ANDA Sponsors Swarm On Vimpat Blockbuster As Protection Expires
Amneal, Glenmark, and Sun Pharma Among Firms With ANDA Approvals
Executive Summary
UCB’s Vimpat blockbuster has finally fallen to generic competition in the US, after its intellectual property was skewered by ANDA sponsors as part of a failed challenge before the US Supreme Court in 2018 and 2019.
You may also be interested in...
Zydus Sets Sight On First US Generic Of UCB’s Briviact
Zydus Cadila has scooped another material ANDA approval from the FDA, with the green light for its generic version of UCB’s Briviact to treat partial-onset seizures.
What’s Next? Five Things To Look Out For In September
As the fourth quarter of the year nears, plenty is on the horizon for industry, with senior management shifts and a slate of high-value launches in the US and Europe.
UCB's Zogenix Bet Pays Out Quickly With Fresh Fintepla Approval
Gaining approval for Fintepla in Lennox-Gastaut syndrome, on top of an earlier green light in Dravet, puts the Belgian group in a strong position to compete with Jazz’s Epidiolex.